Transcranial magnetic stimulation improve... - Cure Parkinson's

Cure Parkinson's

26,569 members27,876 posts

Transcranial magnetic stimulation improves cognition over time in Parkinson's disease September 2019

Bolt_Upright profile image
5 Replies

Not as effective as Caloric Vestibular Stimulation, and some studies have shown it to make things worse, but probably more available.

sciencedirect.com/science/a...

Conclusion

These preliminary findings suggest that active iTBS might improve overall cognitive performance in patients with Parkinson's disease with mild cognitive impairment and that this effect can last up to one month. This cognitive improvement, is likely mediated by improvement on visuospatial abilities. Further studies are needed to explore the potential of iTBS as a therapeutical tool to slow cognitive decline in patients with Parkinson's disease.

Written by
Bolt_Upright profile image
Bolt_Upright
To view profiles and participate in discussions please or .
Read more about...
5 Replies
Bolt_Upright profile image
Bolt_Upright

Published: 19 June 2018 Therapeutic Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Neuroinflammation and Neuroplasticity in Patients with Parkinson’s Disease: a Placebo-Controlled Study

The parallel placebo-controlled study examined the therapeutic effects of dual-target repetitive transcranial magnetic stimulation (rTMS) of the motor cortex (bilaterally) and the left prefrontal cortex (dorsolaterally) on spontaneous and mitogen-stimulating synthesis of pro- and anti-inflammatory cytokines by the blood cells and the level of brain-derived neurotrophic factor (BDNF) in blood serum of patients with Parkinson’s disease. The significantly steeper positive clinical dynamics (assessed by UPRSD scale) observed in rTMS group in comparison with the placebo group was accompanied by a significant drop in spontaneous production of proinflammatory cytokines IFNγ and IL-17A. rTMS produced no significant effect on serum BDNF. The possible mechanisms of rTMS therapeutic action on the level of cytokines associated with neuroinflammation in patients with Parkinson’s disease are discussed.

link.springer.com/article/1...

Bolt_Upright profile image
Bolt_Upright

But not everybody agrees. 2017: Transcranial Magnetic Stimulation Does Not Improve Mild Cognitive Impairment in Parkinson’s Disease

ncbi.nlm.nih.gov/pmc/articl...

Bolt_Upright profile image
Bolt_Upright

Repetitive transcranial magnetic stimulation protects mice against 6-OHDA-induced Parkinson’s disease symptoms by regulating brain amyloid β1–42 level - 2019

link.springer.com/article/1...

Abstract

Repetitive transcranial magnetic stimulation (rTMS) is a technique protecting neurons against diverse neurodegenerative disorders by delivering magnetic stimuli into the brain through the intact scalp. In the current study, the protection effect of rTMS on Parkinson’s disease (PD) and the associated mechanism driving the treatment were explored. The PD symptoms were induced using 6-OHDA in mice, and the effect of rTMS of two frequencies (1 Hz and 10 Hz) on the cognitive behaviors and neuron viability was detected. Afterwards, the level of Aβ1–42 and activity of MKK7-ERK-Fos-APP axis under the administration of rTMS were recorded as well. The intracranial injection of 6-OHDA impaired the cognitive behaviors of the mice in the test of Morris water maze as well as reducing the viability and number of neurons in PD mice. After the treatment of rTMS of both frequencies, the cognitive function of mice was improved and the neuron viability and number were restored in mice brain tissues. The administration of rTMS also increased the cerebrospinal fluid (CSF) level of Aβ1–42 in PD mice, which was accompanied by the suppressed levels of p-MKK7, p-ERK1/2, p–c-Fos, and APP. Moreover, the effect of rTMS on mice nerve system was all exerted in a frequency-dependent manner. In conclusion, the findings outlined in the current study affirmed the protection effect of rTMS against PD. The anti-PD function of rTMS was associated with the suppression of MKK7-ERK-Fos-APP axis, which subsequently resulted in the increased CSF Aβ1–42 level and decreased brain Aβ1–42 level.

in reply toBolt_Upright

Thank you for leaving no stone unturned.

GymBag profile image
GymBag

I thought that we beat the magnetism thing into the ground years ago. It only works on mice and they need to wear a pointy aluminum hat.

Not what you're looking for?

You may also like...

Transcranial Magnetic Stimulation (TMS)

Has anyone here tried TMS and if so for what type of symptomatology? What were your results? I...
gilgamesh profile image

Citicoline as Adjuvant Therapy in Parkinson's Disease: A Systematic Review 2017

Findings A total of 7 studies (2 crossover, 3 randomized controlled, and 2 open prospective...

How much significant is this news?

Annovis Bio Inc. (ANVS) announces patients treated with ANVS401 for 25 days showed statistically...
Farooqji profile image

Vinpocetine regulates levels of circulating TLRs in Parkinson's disease patients 2019

I started today asking "what can I remove from my stack?" And of course, now I am probably adding...

Medicinal cannabis improves outcomes in Parkinson's patients

According to results of a survey of PD patients in Germany in the Journal of Parkinson's Disease,...
Farooqji profile image